CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating

Positive
AI Analysis

Summary

Chardan Capital increased its price target on ProMIS Neurosciences from $20 to $33 per share while maintaining a Buy rating.

Importance:2/10
Sentiment:
0.60
price_target_increaseanalyst_ratingvaluation
Related Companies

Read the original article

Published by yahoo_finance on July 28, 2026 2:46 PM

Read Original